C WorldWide Group Holding A S Has $31.61 Million Position in Natera, Inc. $NTRA

C WorldWide Group Holding A S cut its position in Natera, Inc. (NASDAQ:NTRA) by 16.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 138,000 shares of the medical research company’s stock after selling 27,000 shares during the quarter. Natera accounts for about 0.6% of C WorldWide Group Holding A S’s portfolio, making the stock its 25th largest holding. C WorldWide Group Holding A S’s holdings in Natera were worth $31,614,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Horizon Investments LLC raised its position in shares of Natera by 22.0% in the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock valued at $56,000 after buying an additional 44 shares in the last quarter. Sound Income Strategies LLC raised its position in shares of Natera by 20.0% in the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after buying an additional 45 shares in the last quarter. Savvy Advisors Inc. grew its holdings in shares of Natera by 3.1% during the 4th quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock valued at $353,000 after purchasing an additional 46 shares during the last quarter. Siemens Fonds Invest GmbH grew its holdings in shares of Natera by 3.1% during the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock valued at $290,000 after purchasing an additional 54 shares during the last quarter. Finally, First Horizon Corp grew its holdings in shares of Natera by 7.3% during the 4th quarter. First Horizon Corp now owns 931 shares of the medical research company’s stock valued at $213,000 after purchasing an additional 63 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Natera

In other Natera news, CFO Michael Burkes Brophy sold 482 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $210.49, for a total transaction of $101,456.18. Following the sale, the chief financial officer directly owned 57,496 shares of the company’s stock, valued at $12,102,333.04. The trade was a 0.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 902 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $206.16, for a total transaction of $185,956.32. Following the sale, the chief executive officer directly owned 149,867 shares in the company, valued at $30,896,580.72. The trade was a 0.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 38,266 shares of company stock valued at $7,747,808. 5.63% of the stock is owned by insiders.

Natera Price Performance

NTRA opened at $194.24 on Monday. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $256.36. The firm has a market capitalization of $27.64 billion, a price-to-earnings ratio of -119.17 and a beta of 1.57. The company’s 50 day moving average price is $202.23 and its two-hundred day moving average price is $215.02.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.81. Natera had a negative net margin of 9.05% and a negative return on equity of 15.72%. The firm had revenue of $665.50 million for the quarter, compared to analyst estimates of $600.68 million. During the same period in the previous year, the firm posted ($0.41) EPS. As a group, equities research analysts predict that Natera, Inc. will post -1.71 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on NTRA shares. Wall Street Zen lowered shares of Natera from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a report on Tuesday, April 21st. William Blair started coverage on shares of Natera in a report on Tuesday, April 14th. They set an “outperform” rating on the stock. Morgan Stanley decreased their price target on shares of Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a report on Tuesday, March 3rd. Finally, Canaccord Genuity Group reaffirmed a “buy” rating on shares of Natera in a report on Monday, January 12th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.00.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: JPMorgan raised its price target on Natera to $265 from $260 and kept an overweight rating, signaling confidence in further upside from current levels. JPMorgan raises Natera price target
• Positive Sentiment: Wells Fargo also lifted its target to $220 from $215, indicating continued analyst support despite a more neutral equal-weight stance. Wells Fargo raises Natera price target
• Positive Sentiment: First-quarter revenue came in well above expectations at $696.6 million, up 38.8% year over year, and the company also reported gross margin of 64.7%, showing strong top-line growth. Natera Q1 results
• Neutral Sentiment: Natera updated full-year 2026 revenue guidance to $2.7 billion-$2.8 billion, roughly in line with consensus, which suggests the outlook is steady but not a major surprise. Natera guidance update
• Negative Sentiment: Profitability remains a concern: Natera posted a quarterly loss of $0.60 per share, wider than the expected $0.53 loss, despite the revenue beat. Natera earnings miss
• Negative Sentiment: Recent insider selling, including a CEO stock sale, may add pressure by reinforcing concerns about valuation after the stock’s strong run. Natera CEO stock sale

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.